Addition of epirubicin as a third drug to carboplatin- paclitaxel in first-line treatment of advanced ovarian cancer : A prospectively randomized gynecologic cancer intergroup trial by the arbeitsgemeinschaft gynaekologische onkologie ovarian cancer study group and the groupe d'investigateurs nationaux pour l'etude des cancers ovariens
- Author
- DU BOIS, Andreas; WEBER, Beatrice; RICHTER, Barbara; LUECK, Hans-Joachim; PFISTERER, Jacobus; COSTA, Serban; SCHROEDER, Willibald; KIMMIG, Rainer; PUJADE-LAURAINE, Eric; ROCHON, Justine; MEIER, Werner; GOUPIL, Alain; OLBRICHT, Sigrid; BARATS, Jean-Claude; KUHN, Walther; ORFEUVRE, Hubert; WAGNER, Uwe
[1] Department of Gynecology & Gynecologic Oncology, HSK Dr Horst Schmldt Klinik Wiesbaden, Germany
[2] Department of Gynecology, St Vincentius Khs Karisruhe, KKS Marburg, Coordination Center for Clinical Trials, Germany
[3] Department of Gynecology and Obstetrics, Evangelisches Krankenhaus, Duesseldorf, Germany
[4] Department of Gynecology and Obstetrics, Medizinische Akademie, Magdeburg, Germany
[5] Department of Gynecology and Obstetrics, University Muenchen rechts der Isar, Germany
[6] Department of Gynecology, University Hospital, Tuebingen, Germany
[7] Department of Gynecology and Obstetncs, University of Dresden, Dresden, Germany
[8] Department of Gynecologic Oncology, Medizinische Hochschule, Hannover, Germany
[9] Department of Gynecology and Obstetrics, University Hospital of Schleswig-Holstein Campus Kiel, Germany
[10] Department of Gynecology and Obstetrics, University of Frankfurt, Frankfurt, Germany
[11] Department of Gynecology and Obstetrics, Rheinisch-Westfaelische Technische Hochschule, Aachen, Germany
[12] Department of Gynecology and Obstetrics, University Muenchen- Grosshadern, Germany
[13] Department of Oncology, Centre Alexis-Vautrin, Vandoeuvre-les-Nancy, United States
[14] Department of Oncology, Centre René Huguenin, Saint-Cloud, Germany
[15] Department of Oncology-Hematology, Hôpitaux Civils, Colmar, Germany
[16] Department of Oncology-Hematology, Hôpital Fleyriat, Bourg-en Bresse, Germany
[17] Department of Oncology, Hôpital Hôtel-Dieu, Paris, France - Source
Journal of clinical oncology. 2006, Vol 24, Num 7, pp 1127-1135, 9 p ; ref : 22 ref
- ISSN
- 0732-183X
- Scientific domain
- Medical oncology
- Publisher
- Lippincott Williams & Wilkins, Baltimore, MD
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Anticancéreux Cancer ovaire Cancérologie Carboplatine Epirubicine Essai clinique Médicament Paclitaxel Stade avancé Tumeur maligne Traitement première intention Anthracyclines Antimitotique Appareil génital femelle pathologie Ovaire pathologie Platine II Complexe Taxane dérivé
- Keyword (en)
- Antineoplastic agent Ovary cancer Cancerology Carboplatin Epirubicin Clinical trial Drug Paclitaxel Advanced stage Malignant tumor First line treatment Anthracyclins Antimitotic Female genital diseases Ovarian diseases Platinum II Complexes Taxane derivatives
- Keyword (es)
- Anticanceroso Cáncer del ovario Cancerología Carboplatino Epirubicina Ensayo clínico Medicamento Paclitaxel Estadio avanzado Tumor maligno Tratamiento primer línea Antraciclinas Antimitótico Aparato genital hembra patología Ovario patología Platino II Complejo Taxane derivado
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B20 Gynecology. Andrology. Obstetrics / 002B20C Female genital diseases / 002B20C02 Tumors
- Discipline
- Gynecology. Andrology. Obstetrics Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 17577151
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1200/JCO.2005.03.2938 
https://dx.doi.org/10.1200/JCO.2005.03.2938
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2005.03.2938\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:337:\"Addition of epirubicin as a third drug to carboplatin- paclitaxel in first-line treatment of advanced ovarian cancer : A prospectively randomized gynecologic cancer intergroup trial by the arbeitsgemeinschaft gynaekologische onkologie ovarian cancer study group and the groupe d'investigateurs nationaux pour l'etude des cancers ovariens\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"24\";s:8:\"\u0000*\u0000issue\";s:1:\"7\";s:8:\"\u0000*\u0000spage\";s:4:\"1127\";s:8:\"\u0000*\u0000epage\";s:4:\"1135\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"DU BOIS\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Andreas\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:16:{i:0;s:15:\"WEBER, Beatrice\";i:1;s:16:\"RICHTER, Barbara\";i:2;s:19:\"LUECK, Hans-Joachim\";i:3;s:18:\"PFISTERER, Jacobus\";i:4;s:13:\"COSTA, Serban\";i:5;s:20:\"SCHROEDER, Willibald\";i:6;s:14:\"KIMMIG, Rainer\";i:7;s:21:\"PUJADE-LAURAINE, Eric\";i:8;s:15:\"ROCHON, Justine\";i:9;s:13:\"MEIER, Werner\";i:10;s:13:\"GOUPIL, Alain\";i:11;s:16:\"OLBRICHT, Sigrid\";i:12;s:19:\"BARATS, Jean-Claude\";i:13;s:13:\"KUHN, Walther\";i:14;s:16:\"ORFEUVRE, Hubert\";i:15;s:11:\"WAGNER, Uwe\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:337:\"Addition of epirubicin as a third drug to carboplatin- paclitaxel in first-line treatment of advanced ovarian cancer : A prospectively randomized gynecologic cancer intergroup trial by the arbeitsgemeinschaft gynaekologische onkologie ovarian cancer study group and the groupe d'investigateurs nationaux pour l'etude des cancers ovariens\";s:8:\"\u0000*\u0000place\";s:13:\"Baltimore, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2005.03.2938\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:337:\"Addition of epirubicin as a third drug to carboplatin- paclitaxel in first-line treatment of advanced ovarian cancer : A prospectively randomized gynecologic cancer intergroup trial by the arbeitsgemeinschaft gynaekologische onkologie ovarian cancer study group and the groupe d'investigateurs nationaux pour l'etude des cancers ovariens\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"24\";s:8:\"\u0000*\u0000issue\";s:1:\"7\";s:8:\"\u0000*\u0000spage\";s:4:\"1127\";s:8:\"\u0000*\u0000epage\";s:4:\"1135\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"DU BOIS\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Andreas\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:16:{i:0;s:15:\"WEBER, Beatrice\";i:1;s:16:\"RICHTER, Barbara\";i:2;s:19:\"LUECK, Hans-Joachim\";i:3;s:18:\"PFISTERER, Jacobus\";i:4;s:13:\"COSTA, Serban\";i:5;s:20:\"SCHROEDER, Willibald\";i:6;s:14:\"KIMMIG, Rainer\";i:7;s:21:\"PUJADE-LAURAINE, Eric\";i:8;s:15:\"ROCHON, Justine\";i:9;s:13:\"MEIER, Werner\";i:10;s:13:\"GOUPIL, Alain\";i:11;s:16:\"OLBRICHT, Sigrid\";i:12;s:19:\"BARATS, Jean-Claude\";i:13;s:13:\"KUHN, Walther\";i:14;s:16:\"ORFEUVRE, Hubert\";i:15;s:11:\"WAGNER, Uwe\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:337:\"Addition of epirubicin as a third drug to carboplatin- paclitaxel in first-line treatment of advanced ovarian cancer : A prospectively randomized gynecologic cancer intergroup trial by the arbeitsgemeinschaft gynaekologische onkologie ovarian cancer study group and the groupe d'investigateurs nationaux pour l'etude des cancers ovariens\";s:8:\"\u0000*\u0000place\";s:13:\"Baltimore, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2005.03.2938\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2005.03.2938\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:337:\"Addition of epirubicin as a third drug to carboplatin- paclitaxel in first-line treatment of advanced ovarian cancer : A prospectively randomized gynecologic cancer intergroup trial by the arbeitsgemeinschaft gynaekologische onkologie ovarian cancer study group and the groupe d'investigateurs nationaux pour l'etude des cancers ovariens\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"24\";s:8:\"\u0000*\u0000issue\";s:1:\"7\";s:8:\"\u0000*\u0000spage\";s:4:\"1127\";s:8:\"\u0000*\u0000epage\";s:4:\"1135\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"DU BOIS\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Andreas\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:16:{i:0;s:15:\"WEBER, Beatrice\";i:1;s:16:\"RICHTER, Barbara\";i:2;s:19:\"LUECK, Hans-Joachim\";i:3;s:18:\"PFISTERER, Jacobus\";i:4;s:13:\"COSTA, Serban\";i:5;s:20:\"SCHROEDER, Willibald\";i:6;s:14:\"KIMMIG, Rainer\";i:7;s:21:\"PUJADE-LAURAINE, Eric\";i:8;s:15:\"ROCHON, Justine\";i:9;s:13:\"MEIER, Werner\";i:10;s:13:\"GOUPIL, Alain\";i:11;s:16:\"OLBRICHT, Sigrid\";i:12;s:19:\"BARATS, Jean-Claude\";i:13;s:13:\"KUHN, Walther\";i:14;s:16:\"ORFEUVRE, Hubert\";i:15;s:11:\"WAGNER, Uwe\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:337:\"Addition of epirubicin as a third drug to carboplatin- paclitaxel in first-line treatment of advanced ovarian cancer : A prospectively randomized gynecologic cancer intergroup trial by the arbeitsgemeinschaft gynaekologische onkologie ovarian cancer study group and the groupe d'investigateurs nationaux pour l'etude des cancers ovariens\";s:8:\"\u0000*\u0000place\";s:13:\"Baltimore, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2005.03.2938\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:337:\"Addition of epirubicin as a third drug to carboplatin- paclitaxel in first-line treatment of advanced ovarian cancer : A prospectively randomized gynecologic cancer intergroup trial by the arbeitsgemeinschaft gynaekologische onkologie ovarian cancer study group and the groupe d'investigateurs nationaux pour l'etude des cancers ovariens\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"24\";s:8:\"\u0000*\u0000issue\";s:1:\"7\";s:8:\"\u0000*\u0000spage\";s:4:\"1127\";s:8:\"\u0000*\u0000epage\";s:4:\"1135\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"DU BOIS\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Andreas\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:16:{i:0;s:15:\"WEBER, Beatrice\";i:1;s:16:\"RICHTER, Barbara\";i:2;s:19:\"LUECK, Hans-Joachim\";i:3;s:18:\"PFISTERER, Jacobus\";i:4;s:13:\"COSTA, Serban\";i:5;s:20:\"SCHROEDER, Willibald\";i:6;s:14:\"KIMMIG, Rainer\";i:7;s:21:\"PUJADE-LAURAINE, Eric\";i:8;s:15:\"ROCHON, Justine\";i:9;s:13:\"MEIER, Werner\";i:10;s:13:\"GOUPIL, Alain\";i:11;s:16:\"OLBRICHT, Sigrid\";i:12;s:19:\"BARATS, Jean-Claude\";i:13;s:13:\"KUHN, Walther\";i:14;s:16:\"ORFEUVRE, Hubert\";i:15;s:11:\"WAGNER, Uwe\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:337:\"Addition of epirubicin as a third drug to carboplatin- paclitaxel in first-line treatment of advanced ovarian cancer : A prospectively randomized gynecologic cancer intergroup trial by the arbeitsgemeinschaft gynaekologische onkologie ovarian cancer study group and the groupe d'investigateurs nationaux pour l'etude des cancers ovariens\";s:8:\"\u0000*\u0000place\";s:13:\"Baltimore, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2005.03.2938\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:337:\"Addition of epirubicin as a third drug to carboplatin- paclitaxel in first-line treatment of advanced ovarian cancer : A prospectively randomized gynecologic cancer intergroup trial by the arbeitsgemeinschaft gynaekologische onkologie ovarian cancer study group and the groupe d'investigateurs nationaux pour l'etude des cancers ovariens\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"24\";s:8:\"\u0000*\u0000issue\";s:1:\"7\";s:8:\"\u0000*\u0000spage\";s:4:\"1127\";s:8:\"\u0000*\u0000epage\";s:4:\"1135\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"DU BOIS\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Andreas\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:16:{i:0;s:15:\"WEBER, Beatrice\";i:1;s:16:\"RICHTER, Barbara\";i:2;s:19:\"LUECK, Hans-Joachim\";i:3;s:18:\"PFISTERER, Jacobus\";i:4;s:13:\"COSTA, Serban\";i:5;s:20:\"SCHROEDER, Willibald\";i:6;s:14:\"KIMMIG, Rainer\";i:7;s:21:\"PUJADE-LAURAINE, Eric\";i:8;s:15:\"ROCHON, Justine\";i:9;s:13:\"MEIER, Werner\";i:10;s:13:\"GOUPIL, Alain\";i:11;s:16:\"OLBRICHT, Sigrid\";i:12;s:19:\"BARATS, Jean-Claude\";i:13;s:13:\"KUHN, Walther\";i:14;s:16:\"ORFEUVRE, Hubert\";i:15;s:11:\"WAGNER, Uwe\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:337:\"Addition of epirubicin as a third drug to carboplatin- paclitaxel in first-line treatment of advanced ovarian cancer : A prospectively randomized gynecologic cancer intergroup trial by the arbeitsgemeinschaft gynaekologische onkologie ovarian cancer study group and the groupe d'investigateurs nationaux pour l'etude des cancers ovariens\";s:8:\"\u0000*\u0000place\";s:13:\"Baltimore, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
